{"cache":{"posts_f30bc_88214":{"__typename":"RootQueryToPostConnection","nodes":[{"__typename":"Post","id":"cG9zdDozMDI2Mw==","databaseId":30263,"featuredImage":{"__typename":"NodeWithFeaturedImageToMediaItemConnectionEdge","node":{"__typename":"MediaItem","id":"cG9zdDozMDI3Mw==","altText":"","mediaDetails":{"__typename":"MediaDetails","width":1558,"height":482},"sourceUrl_772ce_bf21a":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Screen-Shot-2022-09-09-at-12.18.28-PM.png","mediaItemUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Screen-Shot-2022-09-09-at-12.18.28-PM.png","title_b28e9_bf21a":"Screen Shot 2022-09-09 at 12.18.28 PM"}},"author":null,"date":"2022-09-12T07:00:41","uri":"/articles/noura-abul-husn-vice-president-genomic-health","title_b28e9_bf21a":"Meet Dr. Noura Abul-Husn, our Vice President of Genomic Health","slug":"noura-abul-husn-vice-president-genomic-health","categories_3cd3e_bf21a":{"__typename":"PostToCategoryConnection","edges":[{"__typename":"PostToCategoryConnectionEdge","node":{"__typename":"Category","id":"dGVybTo4","slug":"inside-23andme","name":"Inside 23andMe","uri":"/category/news/inside-23andme"}},{"__typename":"PostToCategoryConnectionEdge","node":{"__typename":"Category","id":"dGVybTo5","name":"News","uri":"/category/news","seo":{"__typename":"TaxonomySEO","title":"Research Archives - 23andMe Blog","opengraphTitle":"Research Archives","metaDesc":"23andMe research unique research model combines genetic and phenotypic information in what is among the largest databases of its kind.","opengraphDescription":"23andMe research unique research model combines genetic and phenotypic information in what is among the largest databases of its kind.","fullHead":"\n\n\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n"},"slug":"news"}}]},"imageOptions":{"__typename":"Post_Imageoptions","featuredImageSquare":{"__typename":"MediaItem","id":"cG9zdDozMDI2Nw==","mediaDetails":{"__typename":"MediaDetails","sizes_cad4b_bf21a":[{"__typename":"MediaSize","name":"thumbnail","sourceUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop-150x150.png"},{"__typename":"MediaSize","name":"medium","sourceUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop-245x300.png"},{"__typename":"MediaSize","name":"square_sm","sourceUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop-271x271.png"},{"__typename":"MediaSize","name":"square_md","sourceUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop-372x372.png"},{"__typename":"MediaSize","name":"square_lg","sourceUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop-522x574.png"},{"__typename":"MediaSize","name":"wide_sm","sourceUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop-271x149.png"},{"__typename":"MediaSize","name":"wide_md","sourceUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop-372x204.png"},{"__typename":"MediaSize","name":"wide_lg","sourceUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop-522x315.png"},{"__typename":"MediaSize","name":"wide_xl","sourceUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop-522x539.png"}],"height":639,"width":522},"mediaItemUrl":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop.png","sourceUrl_772ce_bf21a":"https://blog-api.23andme.com/wp-content/uploads/2022/09/Noura-Headshot-crop.png"},"singleTemplateFeaturedImage":"none"},"content_b28e9_bf21a":"\n

Here’s Noura Abul-Husn’s recipe for a meaningful career in genomics: Start with curiosity, add adaptability, sprinkle in a willingness to pursue a non-traditional path, and don’t forget to include the most critical ingredient of all – passion.

\n\n\n\n

Following this recipe brought Noura, MD, PhD, to 23andMe, where she recently assumed the role of Vice President of Genomic Health.

\n\n\n\n

Noura spoke with us about her plans to bring genomic medicine into clinical care and her commitment to “keeping people as healthy as possible for as long as possible.”

\n\n\n\n

The following is an edited excerpt of our conversation.

\n\n\n\n

$\"\"$

Noura Abul-Husn, MD, PhD

\n\n\n\n

What inspired you to pursue a career in genetics and genomics?

\n\n\n\n

I initially wanted to do biomedical research. I was always intrigued by science, which was my driving force.

\n\n\n\n

I knew I wanted to get a PhD., but I also needed a strong clinical background to inform the type of research I wanted to do and make it as meaningful as possible to human health.

\n\n\n\n

I initially did an MD-PhD program with the intention of being a scientist, and somewhere along the way, I realized I liked the patient care side of things too.

\n\n\n\n

So, I ended up doing a dual residency in internal medicine and medical genetics. I loved internal medicine because you have to know a little about most diseases that touch adult patients, and I liked the broad scope of understanding human health and disease.

\n\n\n\n

Medical genetics is very different. The way you train for it is you learn about rare diseases that mostly impact pediatric patients. But I was drawn to the specialty because we were starting to understand that genomics touches every aspect of disease in people at every stage of their life.

\n\n\n\n

I felt that a combination of general adult medicine combined with a strong genetics background put me in the position to understand the potential of genomic medicine.

\n\n\n\n

I’ve always been excited about genomics because it’s cutting-edge medicine, and it’s constantly changing. As a result, you have to learn and evolve and think about new ways to innovate.

\n\n\n\n

I also think genomics is central to the future of healthcare, and that future is now. The healthcare industry can leverage the vast amounts of data generated through genomics to keep people as healthy as possible for as long as possible. And though that isn’t happening to the extent that it could be, I think 23andMe is poised to make a real impact.

\n\n\n\n

What are you focused on at 23andMe?

\n\n\n\n

I’m the Vice President of Genomic Health, which is a new position. I’m focused on bringing the 23andMe genetics product into clinical care. I’m thinking about how genetic information can contribute to keeping people healthy, preventing and diagnosing disease, and managing genetic conditions or genetic risks.

\n\n\n\n

I’ll be working closely with the product team and others to execute this new vision and strategy.

\n\n\n\n

What accomplishments are you most proud of?

\n\n\n\n

My biggest personal accomplishment? I had twins! My first instinct when I learned I was having twins was to worry that I would have to stop working and give up on building a career and becoming a leader in this space.

\n\n\n\n

But I persevered, and here we are! (My twins are five now, and they have an older sister – I don’t want to leave her out). I think that was a turning point for me. I had to ask myself, “do I want to continue to work this hard and try to figure things out with an unexpectedly large and growing family?”

\n\n\n\n

\"Noura — *Noura and her oldest daughter hard at work*

\n\n\n\n

Professionally, I took a very non-traditional path as an MD-PhD physician-scientist. First, I started in academia and went to industry for a couple of years. Then I returned to academia, and now I’m back in industry at 23andMe.

\n\n\n\n

In my prior role at Mount Sinai, where I was for four years, I had an opportunity to build something from scratch that I am very proud of. I started a new Division of Genomic Medicine – one of the only divisions of its kind – which had its own Genomic Health Clinic and a unique genomics training program for residents.

\n\n\n\n

We also developed a research program at Mount Sinai focused on expanding the reach of genomic medicine to diverse and underserved populations. I ended up doing many things that may seem different and disparate from each other. Still, they all led towards the same end goal of bringing genomic medicine into clinical care in the most equitable way possible.

\n\n\n\n

What differentiates the work 23andMe is doing from other organizations?

\n\n\n\n

23andMe has always put the consumer – the person – first. They’ve always thought about how to serve a person best and look at that person as an individual using genetic information.

\n\n\n\n

I think that’s extremely powerful. It’s a unique approach to genomic medicine and a unique approach to medicine generally. We practice medicine today based on science that puts people together into cohorts or groups and figures out what medication or management strategy works for most people in that group.

\n\n\n\n

Over the last few decades, we have learned that this one-size-fits-all model doesn’t optimize health for everyone and that we could do better. And we have information at our disposal to make more informed choices, but because it’s a slow-moving field, we don’t optimally use that information the way we could.

\n\n\n\n

23andMe has always had the intention to change that. And that’s what attracted me to this role – the opportunity to leverage genomic information to help us tailor treatment and think about an individual’s risk for developing disease.

\n\n\n\n

The idea of making this a priority for 23andMe is exciting! I can’t emphasize how incredible it is to be a part of this revolution.

\n\n\n\n

\n","seo":{"__typename":"PostTypeSEO","title":"Meet Dr. Noura Abul-Husn, our Vice President of Genomic Health - 23andMe Blog","opengraphTitle":"Meet Dr. Noura Abul-Husn, our Vice President of Genomic Health","metaDesc":"Here’s Noura Abul-Husn’s recipe for a meaningful career in genomics: Start with curiosity, add adaptability, sprinkle in a willingness to pursue a non-traditional path, and don’t forget to include the most critical ingredient of all – passion.","opengraphDescription":"Here’s Noura Abul-Husn’s recipe for a meaningful career in genomics: Start with curiosity, add adaptability, sprinkle in a willingness to pursue a non-traditional path, and don’t forget to include the most critical ingredient of all – passion.","fullHead":"\n\n\n\n\n\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n\n\n\n\t\n\t\n\t\n\n"},"tags_67cce_bf21a":{"__typename":"PostToTagConnection","edges":[{"__typename":"PostToTagConnectionEdge","node":{"__typename":"Tag","id":"dGVybToxMTEz","name":"DEI","uri":"/tag/diversity","seo":{"__typename":"TaxonomySEO","title":"DEI Archives - 23andMe Blog","opengraphTitle":"DEI Archives","metaDesc":"At 23andMe diversity, equity, and inclusion (DEI) are important not just in the workplace, but in the work and science we do.","opengraphDescription":"At 23andMe diversity, equity, and inclusion (DEI) are important not just in the workplace, but in the work and science we do.","fullHead":"\n\n\n\n\n\n\n\n\n\n\n\n\n"}}},{"__typename":"PostToTagConnectionEdge","node":{"__typename":"Tag","id":"dGVybToyOTAy","name":"Featured","uri":"/tag/featured","seo":{"__typename":"TaxonomySEO","title":"Featured Archives - 23andMe Blog","opengraphTitle":"Featured Archives","metaDesc":"","opengraphDescription":"","fullHead":"\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n"}}},{"__typename":"PostToTagConnectionEdge","node":{"__typename":"Tag","id":"dGVybTo0MTE=","uri":"/tag/genomics","name":"genomics","seo":{"__typename":"TaxonomySEO","title":"genomics Archives - 23andMe Blog","opengraphTitle":"genomics Archives","metaDesc":"","opengraphDescription":"","fullHead":"\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n"}}},{"__typename":"PostToTagConnectionEdge","node":{"__typename":"Tag","id":"dGVybToyMTM=","uri":"/tag/personal-genomics","name":"personal genomics","seo":{"__typename":"TaxonomySEO","title":"personal genomics Archives - 23andMe Blog","opengraphTitle":"personal genomics Archives","metaDesc":"","opengraphDescription":"","fullHead":"\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n"}}}]}},{"__typename":"Post","id":"cG9zdDoxNDA4","databaseId":1408,"featuredImage":null,"author":null,"date":"2008-09-18T14:29:47","uri":"/articles/new-study-looks-at-progress-and-potential-for-genomic-medicine-in-developing-nations","title_b28e9_bf21a":"New Study Looks at Progress and Potential for Genomic Medicine in Developing Nations","slug":"new-study-looks-at-progress-and-potential-for-genomic-medicine-in-developing-nations","categories_3cd3e_bf21a":{"__typename":"PostToCategoryConnection","edges":[{"__typename":"PostToCategoryConnectionEdge","node":{"__typename":"Category","id":"dGVybToxNTQx","name":"Health + Traits","slug":"health-traits","uri":"/category/health-traits","seo":{"__typename":"TaxonomySEO","title":"Research Archives - 23andMe Blog","opengraphTitle":"Research Archives","metaDesc":"23andMe research unique research model combines genetic and phenotypic information in what is among the largest databases of its kind.","opengraphDescription":"23andMe research unique research model combines genetic and phenotypic information in what is among the largest databases of its kind.","fullHead":"\n\n\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n"}}}]},"imageOptions":{"__typename":"Post_Imageoptions","featuredImageSquare":null,"singleTemplateFeaturedImage":null},"content_b28e9_bf21a":"

$\"\"$

A special supplement to Nature Reviews Genetics, published online today, details how four countries with emerging economies are building capacity for human genomic variation.

The study looks at Mexico, India, Thailand, and South Africa and steps scientists there are taking to build capacity for genomics and its applications to healthcare.

Following the completion of the HapMap Project, several consortiums in the developed world have undertaken large-scale genotyping projects. The hope is that these efforts will lead to advances in personalized diagnostics and therapeutics that could one day improve health outcomes.

The authors of the six-part series, all from the McLaughlin-Rotman Centre for Global Health (MRC) in Toronto, conclude that similar initiatives in genomic medicine have great potential to help developing countries by strengthening local research infrastructure and local intellectual property regimes, addressing local health needs and reducing health-care costs.

\n(The reports are available free of charge from Nature Genetics with registration)

The highlighted initiatives:

\n
Mexico
\n
\nMexico has formed the National Institute of Genomic Medicine (INMEGEN), the first Mexican institute to systematically describe the genomic diversity of the Mexican population. INMEGEN will allow Mexico to focus on the link between genomic variation in the Mexican population, disease susceptibility and drug-response variability.
\n
India
\n
\nThe Indian Genome Variation (IGV) database is a collaborative network that will capture essential data about disease predisposition, adverse drug reactions (ADRs) and population migration within India.
\n
Thailand
\n
\nThe Thai SNP Discovery Project and the Thai Centre for Excellence in Life Sciences Pharmacogenomics Project will help Thailand understand the genomic diversity of its population and explore the role that this diversity has in drug response and disease susceptibility.
\n
South Africa
\n
\nThe South African government is in the early stages of planning a national genomic medicine research program. Public engagement in genomic issues is spear-headed by The Africa Genome Education Institute.

“The world has reached a historic moment on the path to genomic medicine — the point where theory is about to be translated into practice,” said the project’s principal investigator, Professor Abdallah Daar, in a statement.

“Benefits of this emerging science cannot be an exclusive luxury reserved for wealthier industrialized countries. Instead, it must be universally advanced by developed and developing countries alike to prevent an increased widening of an already huge difference in global health care quality,” said the project leader.

\n","seo":{"__typename":"PostTypeSEO","title":"New Study Looks at Progress and Potential for Genomic Medicine in Developing Nations - 23andMe Blog","opengraphTitle":"New Study Looks at Progress and Potential for Genomic Medicine in Developing Nations","metaDesc":"","opengraphDescription":"A special supplement to Nature Reviews Genetics, published online today, details how four countries with emerging economies are building capacity for human genomic variation. The study looks at Mexico, India, Thailand, and South Africa and steps scientists there are taking to build capacity for genomics and its applications to healthcare. Following the completion of the […]","fullHead":"\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n"},"tags_67cce_bf21a":{"__typename":"PostToTagConnection","edges":[{"__typename":"PostToTagConnectionEdge","node":{"__typename":"Tag","id":"dGVybTo0MTE=","uri":"/tag/genomics","name":"genomics","seo":{"__typename":"TaxonomySEO","title":"genomics Archives - 23andMe Blog","opengraphTitle":"genomics Archives","metaDesc":"","opengraphDescription":"","fullHead":"\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n"}}}]}}],"pageInfo":{"__typename":"RootQueryToPostConnectionPageInfo","hasNextPage":false,"endCursor":"YXJyYXljb25uZWN0aW9uOjE0MDg="}},"tag_0a454_a2b02":{"__typename":"Tag","id":"dGVybTo0MTE=","uri":"/tag/genomics","name":"genomics","seo":{"__typename":"TaxonomySEO","title":"genomics Archives - 23andMe Blog","opengraphTitle":"genomics Archives","metaDesc":"","opengraphDescription":"","fullHead":"\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n"}},"generalSettings":{"__typename":"GeneralSettings","url":"https://blog-api.23andme.com","title":"23andMe Blog","description":"Welcome to The World of Genetics"}}}

genomics

Meet Dr. Noura Abul-Husn, our Vice President of Genomic Health

New Study Looks at Progress and Potential for Genomic Medicine in Developing Nations

Stay in the know.